Диссертация (1173314), страница 18
Текст из файла (страница 18)
66, P. 1154-1164.63.Kusters, J.G. Pathogenesis of Helicobacter pylori infection / J.G.Kusters, A.H. van Vliet, E.J. Kuipers // Clinical microbiology reviews. – 2006. –Vol. 19, № 3. – P. 449-490.64.P. 613-624.Lanas A., Chan F.K. Peptic ulcer disease. Lancet. – 2017. – Vol. 390,12665.Lee J.Y., Park K.S.
Optimal First-Line Treatment for Helicobacterpylori Infection: Recent Strategies // Gastroenterology Research and practice. –2016. Vol. 4, P. 1-7.66.Li B.Z., Threapleton D.E., Wang J.Y., Xu J.M. et al. Comparativeeffectiveness and tolerance of treatments for Helicobacter pylori: systematicreview and network meta-analysis // British medical journal. – 2015. – Vol. 351, P.1-11.67.Liou J.M. The Primary Resistance of Helicobacter pylori in Taiwanafter the National Policy to Restrict Antibiotic Consumption and Its Relation toVirulence Factors-A Nationwide Study / J.M. Liou, C.Y. Chang, M.J.
Chen //PLoS One. – 2015. – Vol. 5, P. 1-11.68.Li-Wan-PoA., GirardT., Farndon P., Cooley C.etal.Pharmacogenetics of CYP2C19: functional and clinical implications of a newvariant CYP2C19*17 // British journal of Clinical pharmacology – 2010. – Vol.69, P. 222-230.69.Luther J., Higgins P.D., Schoenfeld P.S., Moayyedi P. et al. Empiricquadruple vs.
triple therapy for primary treatment of Helicobacter pylori infection:Systematic review and meta-analysis of efficacy and tolerability // Americanjournal of gastroenterology. – 2010. – Vol. 1, P. 65-73.70.Lv Z., Wang B., Zhou X, Wang F. et al. Efficacy and safety ofprobiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis //Experimental and therapeutic medicine. – 2015. – Vol. 9, P. 707-716.71.Malfertheiner P. Management of Helicobacter pylori infection –Maastricht IV / Florence Consensus Report / P.
Malfertheiner, F. Megraud, C.O’Morain [et al.] // Gut. 2012. – Vol. 61, – P. 646-664.72.Malfertheiner P., Megraud F., O'Morain C.A., Gisbert J.P. et al.Management of Helicobacter pylori infection-the Maastricht V/FlorenceConsensus Report // Gut. – 2016. – Vol. 66, P. 6-30.12773.Maev I.V., Andreev D.N., Kucheryavyi Yu.A., Dicheva D.T.
Hostfactors influencing the eradication rate of Helicobacter pylori // World appliedsciences journal. – 2014. – Vol. 30, P. 134-140.74.Megraud F. Helicobacter pylori resistance to antibiotics in Europe andits relationship to antibiotic consumption / F. Megraud, S. Coenen, A. Versporten[et al.] // Gut. – 2013. – Vol. 62, № 1. – P.
34-42.75.MetanatH.A.,ValizadehS.M.,FakheriH.,MalekiI.etal. Comparison between 10- and 14-day hybrid regimens for Helicobacterpylorieradication:A randomized clinical trial // Helicobacter. – 2015. – Vol. 20, P.299-304.76.Molina-Infante J., Gisbert J.P., Fernandez-Bermejo M, Federico A. etal. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the eraof antibiotic resistance // World journal of gastroenterology. – 2014.
– Vol. 20, P.10338-10347.77.Molina-Infante J., Romano M. et al. Optimized nonbismuth quadrupletherapies cure most patients with Helicobacter pylori infection in populations withhigh rates of antibiotic resistance // Gastroenterology. – 2013. Vol. 145, P. 121128.78.Morgan D.R, Crowe S.E. Helicobacter pylori infection. In.: Sleisengerand Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis,Management / edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt.– 10th ed. 2015.79.Oh D.H., Lee D.H., Kang K.K., Park Y.S.
et al. Efficacy of hybridtherapy as first-line regimen for Helicobacter pylori infection compared withsequential therapy // Journal of Gastroenterology and Hepatology. – 2014. Vol.29, P. 1171-1176.80.Padol S., Yuan Y., Thabane M., Padol I.T. et al. The effect ofCYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line128PPI therapies: a meta-analysis // American journal of gastroenterology. – 2006.Vol. 101, P. 1467-1475.81.Puig I., Baylina M., Sánchez-Delgado J., López-Gongora S. et al.Systematic review and meta-analysis: triple therapy combining a proton-pumpinhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment// Journal of antimicrobial chemotherapy.
– 2016. – Vol. 10, P. 2740-2753.82.Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy forHelicobacter pylori infections // Nature reviews gastroenterology and hepatology.– 2011. – Vol. 8, P. 79-88.83.Salih B.A. Helicobacter pylori infection in developing countries: Theburden for how long? / B.A. Salih // Saudi journal of gastroenterology.
– 2009. –Vol. 15, № 3. – P. 201-207.84.Sardarian H., Fakheri H., Hosseini V., Taghvaei T. et al. Comparisonof hybrid and sequential therapies for Helicobacter pylori eradication in Iran: Aprospective randomized trial // Helicobacter. – 2013. – Vol. 18, P. 129-134.85.Song Z.Q., Liu J., Zhou LY. Hybrid Therapy Regimen forHelicobacter Pylori Eradication // Chinese medical journal (Engl). – 2016 – Vol. 8,P.
992-999.86.Song Z.Q., Zhou L.Y. Hybrid, sequential and concomitant therapiesfor Helicobacter pylori eradication: A systematic review and meta-analysis //World journal of gastroenterology. – 2016. – Vol. 22, P. 4766-4775.87.Sugano K., Tack J., Kuipers E.J., Graham D.Y. et al. Kyoto globalconsensus report on Helicobacter pylori gastritis // Gut. 2015. – Vol. 9 – P. 13531367.88.Sun Q., Liang X.
et al. High efficacy of 14-day triple therapy-based,bismuth-containing quadruple therapy for initial Helicobacter pylori eradication //Helicobacter. – 2010. Vol. 15, P. 233-238.12989.Sutton P.1., Boag J.M. Status of vaccine research and development forHelicobacter pylori // Vaccine. – 2018. – P. 1-5.90.Sychev D.A., Denisenko N.P., Sizova Z.M., Grachev A.V. et al. Thefrequency of CYP2C19 genetic polymorphisms in Russian patients with pepticulcers treated with proton pump inhibitors // Pharmgenomics and personalizedmedicine. – 2015. – Vol.
8, P. 111-114.91.Tang H.L., Li Y., Hu Y.F., Xie H.G. et al. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treatedwith proton pump inhibitor-based triple therapy regimens: a meta-analysis ofrandomized clinical trials // PLoS One. – 2013. – Vol. 8, P. 1-9.92.Tonkic A. Epidemiology and diagnosis of Helicobacter pyloriinfection / A. Tonkic, M. Tonkic, P. Lehours [et al.] // Helicobacter. – 2012. – Vol.17, P. 1–8.93.Uotani T., Miftahussurur M., Yamaoka Y. Effect of bacterial and hostfactors on Helicobacter pylori eradication therapy // Expert opinion of therapeutictargets.
– 2015. – Vol. 12, P. 1637-1650.94.Vaira D., Zullo A., Hassan C., Fiorini G. et al. Sequential therapy forHelicobacter pylori eradication:The time is now! // Therapeutic advances ingastroenterology. – 2009. – Vol. 2, P. 317-322.95.Vallve M., Vergara M., Gisbert J.P., Calvet X. et al. Single vs. doubledose of a proton pump inhibitor in triple therapy for Helicobacter pylorieradication: a meta-analysis // Alimentary pharmacology and therapeutics. – 2002.– Vol. 16, P. 1149-1156.96.Venerito M., Krieger T., Ecker T., Leandro G. et al. Meta-analysis ofbismuth quadruple therapy versus clarithromycin triple therapy for empiric primarytreatment of Helicobacter pylori infection // Digestion.
– 2013. – Vol. 1, P. 33-45.97.Versalovic J. Helicobacter pylori. Pathology and diagnostic strategies// American journal of clinical pathology. – 2003. – №119. – С. 403-412.13098.Villoria A., Garcia P., Calvet X., Gisbert J.P. et al. Meta-analysis:high-dose proton pump inhibitors vs. standard dose in triple therapy forHelicobacter pylori eradication // Alimentary pharmacology and therapeutics. –2008. – Vol. 28, P. 868-877.99.Weeks D.L., Eskandari S., Scott D.R., Sachs G. A H+-gated ureachannel: the link between Helicobacter pylori urease and gastric colonization //Science. – 2000.
–Vol. 287, P. 482–485.100. Whary M.T., Fox J.G. Natural and Experimental HelicobacterInfections // Comparative Medicine. Overview / 2004. – Vol. 54, No 2, P. 128-158.101. Wu J.Y., Hsu P.I., Wu D.C., Graham D.Y. Feasibility of shortening14-day hybrid therapy while maintaining an excellent Helicobacter pylorieradication rate // Helicobacter. – 2014. – Vol. 19, N 3, P. 207-213.102.
Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulencefactors // Nature reviews gastroenterology and hepatology. – 2010. Vol. 7, P. 629641.103. Zullo A., De Francesco V., Hassan C., Morini S., et al. The sequentialtherapy regimen for Helicobacter pylori eradication: A pooled-data analysis // Gut.– 2007. – Vol. 56, P. 1353-1357.104. Zullo A., Rinaldi V., Winn S., Meddi P. et al. A new highly effectiveshout term therapy schedule for Helicobacter pylori eradication. Alimentarypharmacology and therapeutics. – 2000.
– Vol. 14, P. 715-718.105. Zullo A., Scaccianoce G., De Francesco V., Ruggiero V.et al.Concomitant, sequential, and hybrid therapy for H pylori eradication: A pilot study// Clinics and research in hepatology and gastroenterology. –2013. – Vol. 37, P.647-650..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
